CDH1 and breast carcinoma: A mesenchymal phenotype with an upregulation of vimentin and downregulation of epithelial markers (E-cadherin and occludin) was obtained in breast cancer cells with stable or transient silencing of Elovl5 expression as assessed at 48 h by western blotting (Fig. 7A) and RT-qPCR (Fig. 7B) while the treatment with DGAT inhibitors (DGAT1i and DGAT2i) reversed the EMT triggered by Elovl5 extinction in breast cancer cells.